| A non-invasive nanoparticle-based sustained dual-drug delivery system as an eyedrop for endophthalmitis B Mahaling, N Baruah, N Ahamad, N Maisha, E Lavik, DS Katti International Journal of Pharmaceutics 606, 120900, 2021 | 16 | 2021 |
| Development of a self-adjuvanting, cross-protective, stable intranasal recombinant vaccine for shigellosis N Baruah, N Ahamad, S Maiti, DR Howlader, U Bhaumik, VV Patil, ... ACS Infectious Diseases 7 (12), 3182-3196, 2021 | 5 | 2021 |
| Stable recombinant Invasion plasmid antigen C (IpaC)-based single dose nanovaccine for shigellosis N Baruah, P Halder, H Koley, DS Katti Molecular Pharmaceutics 19 (11), 3884-3893, 2022 | 3 | 2022 |
| Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology N Baruah, N Ahamad, P Halder, H Koley, DS Katti Journal of Nanobiotechnology 21 (1), 34, 2023 | 1 | 2023 |
| A story of Shigella vaccine development in ICMR-NICED involving multidimensional approaches H Koley, U Bhaumik, N Baruah, S Mitra, S Maiti, D Nag, S Barman, ... Indian Journal of Physiology and Allied Sciences 75 (02), 58-75, 2023 | | 2023 |
| A Comprehensive Computational Investigation into the Conserved Virulent Proteins of Shigella species Unveils Potential Small-Interfering RNA Candidates as a … P Palit, FT Chowdhury, N Baruah, B Sarkar, SN Mou, M Kamal, ... Molecules 27 (6), 1936, 2022 | | 2022 |
| A single-dose nanovaccine for shigellosis and process for synthesis thereof. DSK NB IN Patent App. 202,111,008,181, 2021 | | 2021 |
| Surface Modified Targeted Nanoparticles Carrying Shigella Antigens Confer Cross-protection Against Shigella Infection DSK NB IN Patent 433,684, 2021 | | 2021 |
| Formulation and application of a stable IpaC vaccine against Shigellae in a mouse model N Baruah, S Maiti, DR Howlader, U Bhaumik, N Ahamad, H Koley, MK Chakrabarti ... 54th US-Japan Conference on Cholera and Other Bacterial Enteric Infections, 2019, 2019 | | 2019 |
| Preparation and application of a highly-stable protein antigen against shigellosis and subsequent testing in a nanovaccine. N Baruah, S Maiti, DR Howlader, U Bhaumik, N Ahamad, H Koley, D Katti BioTERM 2019, 2019 | | 2019 |
| A highly-stable therapeutic protein antigen having vaccine application against shigellosis, and a simple and cost-effective method for preparing the same. DSKNB NA IN Patent 455,359, 2019 | | 2019 |
| A simple and cost-effective protein purification system and method thereof. DSKNA NB IN Patent 518,605, 2018 | | 2018 |
| Effect of physicochemical properties of polymeric nanoparticles on in vitro and in vivo toxicity B Mahaling, DAS Rao, N Baruah, N Ahamad, S Sivakumar, E Lavik, ... | | |
Dhirendra KattiProfessor of Biological Sciences and Bioengineering, Indian Institute of Technology KanpurAdresse e-mail validée de iitk.ac.in
